Maiko Niki

415 total citations
16 papers, 322 citations indexed

About

Maiko Niki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Maiko Niki has authored 16 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 2 papers in Neurology. Recurrent topics in Maiko Niki's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Maiko Niki is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Maiko Niki collaborates with scholars based in Japan. Maiko Niki's co-authors include Shosaku� Nomura, Takayasu Kurata, Makoto Ogata, Kayoko Kibata, Aya Nakaya, Hiroshige Yoshioka, Takayuki Miyara, Yuki Takeyasu, Toshihiko Kaneda and Takashi Yokoi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biochemical and Biophysical Research Communications.

In The Last Decade

Maiko Niki

15 papers receiving 322 citations

Peers

Maiko Niki

ONCOL

PRM

IMMUN

SURGE

Shung‐Haur Yang Taiwan

Félix Blanc‐Durand France

Ahmed El‐Balat Germany

Kageaki Watanabe Japan

Edina Tolnay Hungary

Tormund S. Njølstad Norway

Damian J. Ralser Germany

G. Meyberg Germany

Honglei Pei China

Shu-Mei Yan China

Shung‐Haur Yang Taiwan

Maiko Niki

136 ×0.6

ONCOL

81 ×0.5

PRM

54 ×1.1

14 ×0.3

IMMUN

85 ×2.6

SURGE

Citations per year, relative to Maiko Niki Maiko Niki (= 1×) peers Shung‐Haur Yang

Countries citing papers authored by Maiko Niki

Since Specialization

Citations

This map shows the geographic impact of Maiko Niki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maiko Niki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maiko Niki more than expected).

Fields of papers citing papers by Maiko Niki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maiko Niki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maiko Niki. The network helps show where Maiko Niki may publish in the future.

Co-authorship network of co-authors of Maiko Niki

This figure shows the co-authorship network connecting the top 25 collaborators of Maiko Niki. A scholar is included among the top collaborators of Maiko Niki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maiko Niki. Maiko Niki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Shimizu, Takayuki, et al.. (2025). Clinical Impact of Cellular Senescence and RNA Dysregulation in HCC Is Associated With MASLD and HCV-SVR. Anticancer Research. 45(2). 651–659.

Minami, Toshiyuki, Nobuyuki Kondo, Seiichi Hirota, et al.. (2020). Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma. Cancer Science. 111(8). 2895–2906. 19 indexed citations

Mikami, Koji, Takashi Yokoi, Ryo Takahashi, et al.. (2020). Efficacy and safety of nivolumab for malignant mesothelioma in the real world.. Journal of Clinical Oncology. 38(15_suppl). 9052–9052. 1 indexed citations

Minami, Toshiyuki, Y. Nakajima, Maiko Niki, et al.. (2019). EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochemical and Biophysical Research Communications. 519(4). 846–853. 16 indexed citations

Yokoi, Takashi, Seigo Minami, Takayuki Shiroyama, et al.. (2019). A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102. Internal Medicine. 58(10). 1405–1410. 4 indexed citations

Niki, Maiko, Aya Nakaya, Takayasu Kurata, et al.. (2018). Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget. 9(64). 32298–32304. 63 indexed citations

Nakaya, Aya, Takayasu Kurata, Hiroshige Yoshioka, et al.. (2018). Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. International Journal of Clinical Oncology. 23(4). 634–640. 94 indexed citations

Niki, Maiko, Aya Nakaya, Takayasu Kurata, et al.. (2018). Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. Molecular and Clinical Oncology. 10(2). 267–269. 17 indexed citations

Tamaki, Takeshi, et al.. (2017). Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma. Oncology Letters. 13(5). 3695–3702. 9 indexed citations

10.

Nakatani, Yuki, Aya Nakaya, Takayasu Kurata, et al.. (2017). Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer. Case Reports in Oncology. 10(2). 683–688. 2 indexed citations

11.

Nakaya, Aya, Takayasu Kurata, Takashi Yokoi, et al.. (2017). Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer. Molecular and Clinical Oncology. 7(5). 803–807. 7 indexed citations

12.

Sawai, Yusuke, et al.. (2017). Benign metastasizing leiomyoma and 18-FDG-PET/CT: A case report and literature review. Oncology Letters. 14(3). 3641–3646. 24 indexed citations

13.

Kurata, Takayasu, Aya Nakaya, Takashi Yokoi, et al.. (2017). Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. Genes & Cancer. 8(5-6). 559–565. 5 indexed citations

14.

Niki, Maiko, Takashi Yokoi, Takayasu Kurata, & Shosaku� Nomura. (2017). New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. PubMed. Volume 8. 91–99. 18 indexed citations

15.

Nomura, Shosaku�, et al.. (2015). Microparticles as Biomarkers of Blood Coagulation in Cancer. SHILAP Revista de lepidopterología. 7. BIC.S30347–BIC.S30347. 34 indexed citations

16.

Yokoi, Takashi, Yoshitaro Torii, Hiroyuki Sugimoto, et al.. (2014). Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. Oncology Letters. 8(6). 2453–2457. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact